Pegylation: a novel process for modifying pharmacokinetics.
暂无分享,去创建一个
J. M. Harris | N. Martin | J M Harris | M. Modi | N E Martin | M Modi
[1] D. Lacey,et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. , 1995, Blood.
[2] M. Hershfield,et al. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. , 1995, Clinical immunology and immunopathology.
[3] K. Wieder,et al. Enzyme-Polyethylene Glycol Adducts: Modified Enzymes with Unique Properties , 1978 .
[4] M. Hershfield. Biochemistry and Immunology of Poly(ethylene glycol)-Modified Adenosine Deaminase (PEG-ADA) , 1997 .
[5] R. Campbell,et al. Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo. , 2009, Journal of Peptide Research.
[6] J. Reichen,et al. Peginterferon alfa-2a in patients with chronic hepatitis C. , 2000, The New England journal of medicine.
[7] Samuel Zalipsky,et al. Introduction to Chemistry and Biological Applications of Poly(ethylene glycol) , 1997 .
[8] W. Berthold,et al. Polyethylene glycol-conjugated pharmaceutical proteins , 1998 .
[9] R. Offord,et al. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. , 1996, Bioconjugate chemistry.
[10] M. Nucci,et al. The therapeutic value of poly(ethylene glycol)-modified proteins , 1991 .
[11] Nandini V. Katre,et al. The conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential , 1993 .
[12] E. Shaffer,et al. Effect of the prokinetic agent, erythromycin, in the richardson ground squirrel model of cholesterol gallstone disease , 1998, Hepatology.
[13] S. Watanabe,et al. Preparation of long-circulating immunoliposomes containing adriamycin by a novel method to coat immunoliposomes with poly(ethylene glycol). , 1995, Biochimica et biophysica acta.
[14] Y. Tsutsumi,et al. PEGylation of lnterleukin-6 Effectively Increases Its Thrombopoietic Potency , 1997, Thrombosis and Haemostasis.
[15] D. Fisher,et al. Polyethylene glycol modification: relevance of improved methodology to tumour targeting. , 1996, Journal of drug targeting.
[16] A. Neumann,et al. Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.
[17] F. Veronese,et al. Preparation of characterization of poly(ethylene glycol) vinyl sulfone. , 1996, Bioconjugate chemistry.
[18] M. Shiffman,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.
[19] A. Florence,et al. Novel Oral Drug Formulations , 1994, Drug safety.
[20] J. Young,et al. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. , 1988, The Journal of biological chemistry.
[21] S Davis,et al. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. , 1981, Clinical and experimental immunology.
[22] G. Houin,et al. A pharmacokinetic model for alpha interferon administered subcutaneously. , 1999, British journal of clinical pharmacology.
[23] T. Poynard,et al. Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.
[24] V. Mukku,et al. Preparation and Characterization of Poly(ethylene glycol)ylated Human Growth Hormone Antagonist , 1997 .
[25] N L Burnham,et al. Polymers for delivering peptides and proteins. , 1994, American journal of hospital pharmacy.
[26] C Delgado,et al. The uses and properties of PEG-linked proteins. , 1992, Critical reviews in therapeutic drug carrier systems.
[27] M. Newman,et al. Safety of Poly(ethylene glycol) and Poly(ethylene glycol) Derivatives , 1997 .
[28] Y. Ikada,et al. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. , 1994, Journal of pharmaceutical sciences.
[29] S. Pizzo,et al. A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. , 1983, Analytical biochemistry.
[30] J. Szebeni,et al. The interaction of liposomes with the complement system. , 1998, Critical reviews in therapeutic drug carrier systems.
[31] D. Northfelt,et al. Population pharmacokinetics and pharmacodynamics of pegylated‐liposomal doxorubicin in patients with AIDS‐related Kaposi's sarcoma , 1997, Clinical pharmacology and therapeutics.
[32] D. Gibson,et al. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection , 1984, Clinical pharmacology and therapeutics.
[33] B. Ferraiolo,et al. The Role of Pharmacokinetics in the Development of Biotechnologically Derived Agents , 1992, Clinical pharmacokinetics.
[34] S. Pizzo,et al. A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function. , 1985, The Journal of clinical investigation.
[35] Y. Tsutsumi,et al. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. , 1995, British Journal of Cancer.
[36] William M. Lee,et al. Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C , 2001 .
[37] P. Caliceti,et al. A branched monomethoxypoly(ethylene glycol) for protein modification. , 1995, Bioconjugate chemistry.
[38] S. Stewart,et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] L. Holle. Pegaspargase: An Alternative? , 1997, The Annals of pharmacotherapy.
[40] C. Dash,et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. , 1998, British journal of clinical pharmacology.
[41] D. Mould,et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa‐2a and a polyethylene glycol‐modified derivative in healthy subjects , 1996, Clinical pharmacology and therapeutics.
[42] T. Allen,et al. Liposomes , 2012, Drugs.
[43] M. Keating,et al. L-asparaginase and PEG asparaginase--past, present, and future. , 1993, Leukemia & lymphoma.